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Background
In this study we investigated the efficacy and safety of
subcutaneous allergen immunotherapy (AIT) with Der-
matophagoides pteronyssinus (DP) in patients with local
allergic rhinitis (LAR).
Methods
A randomized, double-blind, placebo-controled, parallel-
group, phase II study was conducted. Thirty-six subjects
with LAR to DP were randomized to receive Pangra-
minâ PLUS, ALK, Dermatophagoides pteronyssinus
(AIT-DP) or placebo for 24 months. The primary end-
point was total symptoms (TSS) and total medication
scores (TMS). Secondary endpoints included: total com-
bined symptom+medication scores (TCS), daily symp-
toms score (DSS), daily medication score (DMS),
medication free days (MFD), skin testing, nasal allergen
provocation test (NAPT-DP), and adverse events. Serum
and nasal lavage samples were obtained for immunologi-
cal studies.
Results
Twenty-eight patients completed the study. AIT-DP
produced a significant improvement in the primary end-
points compared to placebo (a 47% of reduction in TSS
(0.60 vs 1.14; p<0.001) and a 51.2% in TMS (0.65 vs
1.34; p=0.002). Moreover, at 6-12-18-24 months signifi-
cant improvements in TCS (p=0.046; p=0.037; p=0.011;
p=0.007) and DSS (p=0.003; p=0.012; p<0.001; p<0.001);
and at 24 months in DMS (p=0.014), and MFD
(p=0.031) compared to placebo were observed. AIT-DP
induced an objective improvement in nasal tolerance to
NAPT-DP at 6-12-18-24 months (p=0.003; p<0.001;
p<0.001; p<0.001) compared to placebo, with negative
responses in the 50% of patients. AIT-DP was well-
tolerated, one patient had a local moderate reaction
solved without systemic treatment. No systemic reac-
tions occurred.
Conclusion
We prove that AIT with Dermatophagoides Pteronyssi-
nus is an effective and well-tolerated treatment in LAR
patients. This phase II study provides the indication for
AIT in LAR.
Authors’ details
1Allergy Unit, Regional University Hospital of Málaga, Spain. 2Allergy Service,
Hospital Infanta Leonor, Spain.
Published: 8 April 2015
doi:10.1186/1939-4551-8-S1-A263
Cite this article as: Rondon et al.: Subcutaneous allergen
immunotherapy with dermatophagoides pteronyssinus in patient with
local allergic rhinitis. World Allergy Organization Journal 2015 8(Suppl 1):
A263.
1Allergy Unit, Regional University Hospital of Málaga, Spain
Full list of author information is available at the end of the article
Rondon et al. World Allergy Organization Journal 2015, 8(Suppl 1):A263
http://www.waojournal.org/content/8/S1/A263
© 2015 Rondon et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
